| Nov 18 |
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
|
| Nov 18 |
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
|
| Nov 5 |
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
|
| Nov 4 |
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
|
| Nov 1 |
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
|
| Oct 14 |
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
| Oct 9 |
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ...
|
| Oct 3 |
Arrowhead: A First Approval Likely - Jury Still Out On Investment Opportunity
|
| Sep 24 |
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
|
| Sep 23 |
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
|
